Background: Tyrosine kinase inhibitors (TKIs) have dramatically improved survival for patients with chronic myelogenous leukemia (CML). However, there are growing evidences that TKIs may be associated with an increased risk of cardiovascular events. Methods: We searched MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) databases. Included studies were: (1) randomized controlled trials or cohort studies of adult patients ( ≥ 18 years) treated with TKIs for chronic phase or accelerated phase CML, (2) studies that reported at least one cardiovascular outcome (peripheral arterial occlusive disease (PAOD), ischemic heart disease or stroke/TIA). The primary outcome of this review were a composite of major cardiovascular events. The pooled incidences of cardiovascular events with corresponding 95% confidence intervals [CI] were performed using a single-proportion random-effects model. The pooled risk ratio (RR) with 95% CIs was calculated using a Mantel-Haenszel random-effects model to compare the effect between nilotinib and imatinib. Results: We identified 32 studies enrolling 16,218 patients (20 studies investigated nilotinib, 12 imatinib, 4 ponatinib, 1 dasatinib and 1 bosutinib). The pooled incidence rates (95% CI) of cardiovascular events were 8% (6-10%) for nilotinib, 1% (0-1%) for imatinib, 2% (1-2%) for dasatinib, 10% (5-16%) for ponatinib and 13% (11-16%) for bosutinib and 6% (3-10%) for non-TKI studies. The direct comparison between nilotinib and imatinib suggested that nilotinib treatment was associated with a significantly increased risk of the cardiovascular events (RR 1.6; 95%CI 1.4-1.8). Conclusions: Here, we evaluated the pooled estimates of the incidence of cardiovascular events in CML patients treated with TKIs. The pool proportions suggested that, when compared to non-TKI treated patients, patients who received imatinib and dasatinib had lesser cardiovascular events, whereas the incidence was greater among patients receiving nilotinib, ponatinib and bosutinib.